Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iPS Differentiated Cardiomyocytes for Chronic Heart Failure
NCT03759405Phase 3Unknown
- Sponsor
- Beijing University of Chinese Medicine
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 3, open-label trial in chronic heart failure (CHF), sponsored by Beijing University of Chinese Medicine. Primary endpoints: Quality of life assessment at 26 weeks and Curative effect evaluation at 26 weeks. Status: unknown.
02
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT03759405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03759405.